🇺🇸 FDA
Patent

US 9193722

Tri-cyclic pyrazolopyridine kinase inhibitors

granted A61KA61K31/496A61K31/506

Quick answer

US patent 9193722 (Tri-cyclic pyrazolopyridine kinase inhibitors) held by Vertex Pharmaceuticals Incorporated expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Nov 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/496, A61K31/506, A61P, A61P1/00